Orchestra BioMed Holdings, Inc. (OBIO)
NASDAQ: OBIO · Real-Time Price · USD
5.95
+0.22 (3.84%)
Oct 9, 2026, 4:00 PM EDT - Market closed

Orchestra BioMed Holdings Stock Forecast

Stock Price Forecast

According to 7 analysts polled by S&P Global, Orchestra BioMed Holdings stock has a consensus rating of "Strong Buy" and an average price target of $12.43. The average 1-year stock price forecast is 108.91% higher than the current stock price, while the lowest is $9.00 (+51.26%) and the highest is $20 (+236.13%).

Price Target: $12.43 (+108.91%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$9.00$12.43$11$20
Change+51.26%+108.91%+84.87%+236.13%

Analyst Ratings

The average analyst rating for Orchestra BioMed Holdings stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingMay '26Jun '26Jul '26Aug '26Sep '26Oct '26
Strong Buy555566
Buy111111
Hold111100
Sell000000
Strong Sell000000
Total777777

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$10
BuyReiterates$10+68.07%Oct 5, 2026
B. Riley Securities
B. Riley Securities
Buy
Reiterates
$11
BuyReiterates$11+84.87%Oct 2, 2026
TD Cowen
TD Cowen
Buy
Reiterates
$15
BuyReiterates$15+152.10%Sep 25, 2026
BTIG
BTIG
Buy
Upgrades
$10
BuyUpgrades$10+68.07%Sep 10, 2026
Piper Sandler
Piper Sandler
Buy
Reiterates
$9 → $10
BuyReiterates$9 → $10+68.07%Aug 11, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
451.14K
from 33.48M
Decreased by -98.65%
Revenue Next Year
600.14K
from 451.14K
Increased by 33.03%
EPS This Year
-1.52
from -1.11
EPS Next Year
-1.51
from -1.52
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
-782.00K3.53M2.76M2.64M33.48M451.14K
Revenue Growth
---21.88%-4.42%1,169.22%-98.65%
Operating Income
-21.80M-32.66M-51.51M-64.30M-51.81M-93.71M
Net Income
-23.01M-33.61M-49.12M-61.02M-52.70M-96.28M
EPS
-----1.11-1.52
Free Cash Flow
-----49.45M-82.95M
No. Analysts
-----7
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High700,000
Avg451,140
Low378,000

Revenue Growth

Revenue Growth202620272028
High
-97.9%
Avg
-98.7%
Low
-98.9%

EPS Forecast

EPS202620272028
High-1.46
Avg-1.52
Low-1.65

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-